beta-catenin has a role in cell adhesion and Wnt signaling. It is mutated or otherwise dysregulated in a variety of human cancers. In this study we assess beta-catenin alteration in 145 thyroid tumors samples from 127 patients. beta-catenin was localized using immunofluorescence and mutational analysis was performed by single-strand conformational polymorphism. Membrane beta-catenin expression was decreased in eight of 12 (66%) adenomas and in all 115 carcinomas (P: < 0.0001). Among carcinomas, reduced membrane beta-catenin was associated with progressive loss of tumor differentiation (P: < 0.0001). CTNNB1 exon 3 mutations and nuclear beta-catenin localization were restricted to poorly differentiated [7 of 28 (25%) and 6 of 28 cases (21.4%), respectively] or undifferentiated carcinomas [19 of 29 (65.5%) and 14 of 29 (48.3%) cases, respectively]. Poorly differentiated tumors always featured mutations involving Ser and Thr residues and were characterized by Thr to Ile amino acid substitutions (P: = 0.0283). The association between CTNNB1 exon 3 mutations and aberrant nuclear immunoreactivity (P: = 0.0020) is consistent with Wnt activation because of stabilizing beta-catenin mutations. Low membrane beta-catenin expression as well as its nuclear localization or CTNNB1 exon 3 mutations are significantly associated with poor prognosis, independent of conventional prognostic indicators for thyroid cancer but not of tumor differentiation. Analysis of beta-catenin dysregulation may be useful to objectively subtype thyroid neoplasms and more accurately predict outcomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1850336 | PMC |
| http://dx.doi.org/10.1016/s0002-9440(10)64045-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lymphoid enhancer-binding factor 1 (LEF1) immunostaining as a surrogate for β-catenin () mutations.
J Clin Pathol
December 2024
Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
Aims: Mutations affecting exon 3 of the β-catenin () gene result in constitutive activation of WNT signalling and are a diagnostic hallmark of several tumour entities including desmoid-type fibromatosis. They also define clinically relevant tumour subtypes within certain entities, such as endometrioid carcinoma. In diagnostics, β-catenin immunohistochemistry is widely used as a surrogate for mutations.
View Article and Find Full Text PDFCD73 restrains mutant β-catenin oncogenic activity in endometrial carcinomas.
bioRxiv
November 2024
Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.
Missense mutations in exon 3 of , the gene encoding β-catenin, are associated with poor outcomes in endometrial carcinomas (EC). Clinically, mutation status has been difficult to use as a predictive biomarker as β-catenin oncogenic activity is modified by other factors, and these determinants are unknown. Here we reveal that CD73 restrains the oncogenic activity of exon 3 β-catenin mutants, and its loss associates with recurrence.
View Article and Find Full Text PDFCorrelation between CTNNB1 mutation status and tumour phenotype in hepatitis B virus-related hepatocellular carcinoma.
Histopathology
November 2024
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Aims: The frequency of CTNNB1 mutation, one of the most frequent genetic events in hepatocellular carcinoma (HCC), is lower in Asian countries and in hepatitis B virus (HBV)-related HCCs. In this study, we evaluated the prevalence and types of CTNNB1-mutation in HBV-related HCC and correlated the molecular status with the histomorphological and immunohistochemical features.
Methods And Results: A total of 108 consecutive cases of treatment-naïve, surgically resected HBV-related HCCs were selected.
Pilomatrix-like breast carcinoma: A mammary analog of pilomatrix-like high-grade endometrioid carcinoma (PiMHEC).
Am J Clin Pathol
October 2024
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US.
Article Synopsis
- - This study presents the first recognized case of triple-negative breast carcinoma (TNBC) that has a PiMHEC-like phenotype, characterized by certain defining features such as high-grade morphology and specific mutations.
- - The tumor was found adjacent to a HER2-positive invasive ductal carcinoma, showing different marker expressions and mutations, suggesting a clonal relationship between the two components.
- - Overall, the findings indicate that a PiMHEC-like TNBC can develop from conventional invasive ductal carcinoma, potentially explaining a lack of response to typical chemotherapy treatments.
Circulating Tumor DNA in Patients with Desmoid Fibromatosis during Active Surveillance.
Ann Surg Oncol
December 2024
Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Article Synopsis
- Sporadic desmoid fibromatosis (DF) is a rare and aggressive tumor linked to mutations in the CTNNB1 gene, with standard treatment being active surveillance, although 30% may require additional therapy due to unpredictable disease progression.
- In a study involving 56 patients, the researchers analyzed both tumor biopsies and plasma samples to assess the presence and quantity of circulating tumor DNA (ctDNA) correlating to CTNNB1 mutations, finding varying detection rates for different mutations.
- The findings suggest a potential role for ctDNA as a diagnostic tool to monitor disease progression, warranting further clinical trials to determine its effectiveness as a predictive biomarker in managing sporadic DF.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!